At IgGenix, our mission is to develop a first-in-class therapy for millions of people whose daily lives are limited by food allergies and other severe allergic conditions.
Starting from a deep understanding of molecular immunology, we employ an antibody-based therapeutic platform to potentially enable faster, deeper and more sustained clinical responses. We push the limits of single-cell genomic technology to capture and analyze very rare human B cells expressing allergen binding antibodies. We engineer these antibodies to uniquely capture allergens and endow them with powerful immune modulating activities derived from the IgG antibody class to suppress allergic reactions. Our team is at work today to make this new life changing therapy tomorrow’s reality.
The IgGenix Team
MANAGEMENT
Richard Boismenu, Ph.D.
Chief Scientific Officer
Derek Croote, Ph.D.
Chief Technical Officer
SCIENTIFIC CO-FOUNDERS
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Biohub
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.
Stanford University
BOARD OF DIRECTORS
Jessica Grossman, M.D
IgGenix
Samir Kaul
Khosla Ventures
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Biohub
SCIENTIFIC ADVISORY BOARD
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I. (Chairperson)
Stanford University
Hans Oettgen, M.D., Ph.D.
Harvard Medical School
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Biohub
Scott Smith, M.D., Ph.D.
Vanderbilt University
Dale Umetsu, M.D., Ph.D.
Stanford University; University of California, San Francisco
Jim Wells, Ph.D.
University of California, San Francisco
Technology
IgGenix is taking a revolutionary approach to directly address food allergies by re-engineering key antibodies involved in the allergic cascade. We believe we can truly change the face of allergic disease, empowering people to live life without the constant fear of a life-threatening allergic reaction.
Recent studies indicate that food allergies affect more than 200 million individuals worldwide, including 11% of adults and between
Few options exist for adults and children who suffer from severe food allergies, and none exist that treat the underlying mechanism of disease. In individuals with allergies, specialized B cells produce IgE antibodies to each specific allergen. The IgE antibodies bind to mast cells, initiating what can be a life-threatening cascade when an individual is exposed to an allergen. This cascade happens quickly and can result in anaphylaxis and even death.
Through its unique technology, IgGenix isolates and re-engineers allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent an allergic cascade. Through this completely novel approach to treating allergic disease, IgGenix’s treatments may be able to effectively block and even prevent life-threatening allergic reactions, while at the same time elucidating the role of the allergens themselves.
Publications
- Croote, D. et al, “High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes.” Science, Vol. 362, Issue 6420, 2018. pp. 1306-1309.
- Gould, H. et al, “Peanut allergen-specific antibodies go public.” Science, Vol. 362, Issue 6420, 2018. pp. 1247-1248.
Investors
Careers
We are a small, innovative and passionate team working in a fast-paced environment at the forefront of allergy immunology. We have exciting opportunities for enthusiastic, self-motivated, and detail-oriented individuals to join the growing team at IgGenix. IgGenix offers competitive compensation, comprehensive benefits, equity, and the opportunity for growth.
Scroll through our list of open positions and apply today!
For more information contact us at HR@IgGenix.com.
Current Job Opportunities
Contact
IgGenix, Inc
329 Oyster Point Blvd., 3rd Floor
South San Francisco, CA 94080
650-491-9626
info@IgGenix.com